Mature vessel occlusion after anti-VEGF treatment in a retinal arteriovenous malformation
© Chuang et al.; licensee BioMed Central Ltd. 2013
Received: 18 May 2013
Accepted: 9 October 2013
Published: 21 October 2013
To report engorged vessel occlusion after repeated intravitreal injections of bevacizumab to treat the macular oedema in a case of arteriovenous malformation.
A 37-year-old woman presented with a sudden, painless loss of vision in her left eye. Her visual acuity was 20/200 in the left eye, and 20/20 in the right eye. Ophthalmoscopic examination revealed an abnormal tangle of vessels and enlarged draining veins. A fluorescence angiogram revealed fluorescence leakage at a turn near the fovea. Horizontally oriented optical coherence tomography revealed an increased macular thickness and an accumulation of intraretinal fluid, indicating macular oedema. After three intravitreal injections of 1.25 mg bevacizumab, her vision improved to 20/20. Ophthalmoscopic examination revealed a decreased calibre of the previously engorged draining veins and ghost vessels. Repeated horizontally oriented optical coherence tomography revealed a decreased macular thickness and the absence of an intraretinal cyst. At the 2-year follow-up visit, the vision of the patient was stable.
This finding implies that certain middle-size vessels can become occluded during anti- vascular endothelium growth factor (anti-VEGF) therapy, which could induce fatal complications if it occurred in the heart or brain. Clinicians should be cautious of the potential thrombotic effects on systemic blood vessels when administering anti-VEGF treatment.
Anti-vascular endothelium growth factor (anti-VEGF) agents have antiangiogenic and oedema-diminishing actions and are used widely to diminish new vessels and reduce the oedema of ocular diseases [1–4]. Anti-VEGF is believed to diminish new vessels but not mature vessels and is therefore considered to be a relatively safe therapy [1–4]. Herein, we report the first case of a grade 1 retinal arteriovenous (AV) malformation  in which the patient regained vision after repeated intravitreal injections of bevacizumab. Unexpectedly, we observed occlusion of the engorged vessels after repeated intravitreal injections of bevacizumab to treat the macular oedema.
In the present case, we chose to use anti-VEGF because we observed fluorescence leakage and retinal oedema during optical coherence tomography. Although the vision of the patient improved to 20/20 and remained stable for 2 years after the three intravitreal injections of bevacizumab, the regression of the abnormal, engorged mature vessels after treatment was unexpected. This thromboembolic event can be explained by either spontaneous involution or induced platelet aggregation followed by degranulation and thrombosis through the formation of a complex with VEGF and activation of the platelet FcγRIIa receptor . This finding represents the case-report of a single individual and must be studied more extensively before it can be generalised on a larger basis or used to determine a standard of care. However, clinicians should be cautious of the potential thrombotic effects on systemic blood vessels when administering anti-VEGF treatment.
Written informed consent was obtained from the patient for the publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor of this journal.
Vascular endothelium growth factor.
Funding was provided through grants CMRPG390271 and CMRPG3A0591 from Chang Gung Memorial Hospital, Linkou, Taiwan.
- Rajendram R, Fraser-Bell S, Kaines A, et al: A 2-year prospective randomized controlled trial of Intravitreal Bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24-month data: report 3. Arch Ophthalmol. 2012, 130: 972-979. 10.1001/archophthalmol.2012.393.View ArticlePubMedGoogle Scholar
- Martin DF, Maguire MG, Fine SL, et al: Ranibizumab and Bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmol. 2012, 119: 1388-1398. 10.1016/j.ophtha.2012.03.053.View ArticleGoogle Scholar
- Mintz-Hittner HA, Kennedy KA, Chuang AZ: Efficacy of Intravitreal Bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med. 2011, 364: 603-615. 10.1056/NEJMoa1007374.View ArticlePubMedPubMed CentralGoogle Scholar
- Martin DF, Maguire MG, Ying GS, et al: Ranibizumab and Bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011, 364: 1897-1908.View ArticlePubMedGoogle Scholar
- Archer DB, Deutman A, Ernest JT, Krill AE: Arteriovenous communications of the retina. Am J Ophthalmol. 1973, 75: 224-41.View ArticlePubMedGoogle Scholar
- Meyer T, Robles-Carrillo L, Robson T, et al: Bevacizumab immune complexes activate platelets and induce thrombosis in FCGR2A transgenic mice. J Thromb Haemost. 2009, 7: 171-181. 10.1111/j.1538-7836.2008.03212.x.View ArticlePubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2415/13/60/prepub
This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.